Trial Profile
A Randomized, Double-blind, Placebo-controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bitopertin (Primary)
- Indications Schizophrenia
- Focus Biomarker; Therapeutic Use
- Sponsors Roche
- 17 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 20 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2014 to 1 Feb 2014.
- 20 Feb 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.